Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

(MedPage Today) -- Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved...